William H. Sauer, MD, FHRS, CCDS, Brigham and Women’s Hospital is joined by Sanjay Divakaran, MD, MPH, Brigham and Women’s Hospital and Xiaoxiao Qian, MD, Brigham, and Women’s Hospital to discuss the 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/magnetic resonance (MR) can identify inflammation and fibrosis, which are high-risk features in cardiac sarcoidosis.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Pricing
CME included with membership
| Heart Rhythm 2025 On Demand – Member | $649 |
| Heart Rhythm 2025 On Demand – Non-Member | $749 |
| Heart Rhythm 365 PLUS Subscription (low end) | $49 |
| Heart Rhythm 365 PLUS Subscription (high end) | $999 |
| Free Content (Health Economics, The Lead, Journal Watch) | Free |
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 0.25 credits
- MOC · Up to 0.25 points
-
ReleasedNov 27, 2024
-
Last day to claim creditNov 28, 2027 1 year left
-
American Society of Echocardiography The Role of Cardiac Imaging in Cardiac Sarcoidosis and Cardiac Tamponade
-
University of Chicago School of Medicine FSR Sarcoidosis Journal Club
-
American Society of Nuclear Cardiology JNC: Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01) (Q2_26)
-
Heart Rhythm Society The Lead Episode 84: A Discussion of Arrhythmic prognosis according to left ventricular systolic dysfunction severity in cardiac sarcoidosis
-
Heart Rhythm Society The Lead Episode 94: A Discussion of Atrial Fibrillation Nomenclature, definitions, and Mechanisms: Position paper from the International Working Group of the Signal Summit
-
Heart Rhythm Society The Lead Episode 93: Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
